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Aims - In vivo platelet function is a product of intrinsic platelet reactivity, modifiable by dual 3	
antiplatelet therapy (DAPT), and the extrinsic inhibitory endothelial mediators, nitric oxide 4	
(NO) and prostacyclin (PGI2), that are powerfully potentiated by P2Y12 receptor blockade. 5	
This implies that for individual patients endothelial mediator production is an important 6	
determinant of DAPT effectiveness. Here, we have investigated this idea using platelets 7	
taken from healthy volunteers treated with anti-platelet drugs. 8	
Methods - Three groups of male volunteers (n=8) received either prasugrel (10 mg), aspirin 9	
(75 mg) or DAPT (prasugrel + aspirin) once daily for 7 days. Platelet reactivity in the 10	
presence of DEA/NONOate and PGI2 was studied before and following treatment. 11	
Results - Ex vivo, PGI2 and/or DEA/NONOate had little inhibitory effect on TRAP-6-induced 12	
platelet reactivity in control conditions. However, in the presence of DAPT, combination of 13	
DEA/NONOate+PGI2 reduced platelet aggregation (74±3% to 19±6%, p<0.05). In vitro 14	
studies showed even partial (25%) P2Y12 receptor blockade produced a significant (67±2% 15	
to 39±10%, p<0.05) inhibition when DEA/NONOate+PGI2 was present. 16	
Conclusions - We demonstrate that PGI2 and NO synergise with P2Y12 receptor 17	
antagonists to produce powerful platelet inhibition. Furthermore, even with submaximal 18	
P2Y12 blockade the presence of PGI2 and NO greatly enhances platelet inhibition. Our 19	
findings highlight the importance of endothelial mediator in vivo modulation of P2Y12 20	
inhibition and introduces the concept of refining ex vivo platelet function testing by 21	
incorporating an assessment of endothelial function to better predict thrombotic outcomes 22	
and adjust therapy to prevent adverse outcomes in individual patients.  23	
24	
	 3 
What is already known about this subject 1	
• Platelet function is a product of intrinsic platelet reactivity. 2	
• This can be modified by dual anti-platelet therapy (DAPT), but also by the 3	
influence of the endothelial mediators, nitric oxide (NO) and prostacyclin (PGI2).  4	
• NO and PGI2 also independently amplify each other’s effects. 5	
 6	
What this study adds 7	
• Three-way synergy between PGI2, NO and P2Y12 receptor antagonism produces 8	
powerful platelet inhibition.  9	
• Even with submaximal (25%) P2Y12 blockade, the presence of PGI2 and NO 10	
greatly enhances platelet inhibition.  11	
• Assessing endothelial mediator production and associations to platelet cyclic 12	





Compromise in the integrity of the vascular endothelium precipitates rapid platelet activation 2	
as platelets become exposed to sub-endothelial collagen and tissue factor. This activation is 3	
driven by a cascade of complex intracellular signaling pathways leading to the production of 4	
secondary platelet agonists, notably thromboxane (TX) A2 and ADP [1, 2]. Dual anti-platelet 5	
therapy (DAPT) is recommended for the secondary prevention of atherothrombotic events in 6	
patients with acute coronary syndromes or following percutaneous coronary intervention [3, 7	
4] and targets these two pathways with a P2Y12 receptor antagonist, such as clopidogrel, 8	
prasugrel or ticagrelor, and aspirin. The P2Y12 receptor blockers inhibit platelet aggregation 9	
by blocking the amplifying effects of ADP acting on platelet P2Y12 receptors [5], while aspirin 10	
targets the TXA2-dependent pathway by inhibiting the cyclooxygenase (COX) enzyme within 11	
platelets [6]. Whilst DAPT is associated with an improvement in patient outcomes, 12	
thrombotic events do still occur. An often explored hypothesis is that the risk of experiencing 13	
a thrombotic event is associated with the level of platelet blockade: i.e. those individuals with 14	
less effective blockade provided by aspirin and, particularly, P2Y12 receptor blockers are 15	
more at risk of thrombotic events. However, studies have failed to show any benefits from ex 16	
vivo monitoring of platelet function and subsequent tailoring of treatment in patients 17	
receiving dual anti-platelet therapy [7–10]. This failure is possibly because the ex vivo 18	
platelet tests used in these trials do not consider the environment in which platelets reside in 19	
vivo. Namely that within the circulation endothelium-derived autacoids, nitric oxide (NO) and 20	
prostacyclin (PGI2), reduce platelet reactivity and prevent inappropriate platelet activation 21	
[11, 12]. Indeed, within the circulation each platelet is balanced by approximately 50 22	
endothelial cells (e.g. 1.25 trillion platelets vs. 60 trillion endothelial cells in a 70 kg man) 23	
[13].  24	
NO diffuses freely into platelets activating guanylyl cyclase (GC) to increase intracellular 25	
cGMP levels [14], while PGI2 binds to IP receptors activating adenylyl cyclase (AC) to 26	
	 5 
increase intracellular cAMP levels [15]. Elevations in the intracellular levels of individual 1	
cyclic nucleotides promotes a generalised inhibition of platelet function [16] and the two 2	
pathways synergise to produce particularly strong inhibition [12]. NO and PGI2 also 3	
individually synergise with P2Y12 inhibition producing robust anti-aggregatory platelet effects 4	
[17, 18]. 5	
Taking account of the above observations we hypothesised that within the circulation the 6	
levels of endothelium-derived mediators are an important determinant of the efficacy of 7	
DAPT. Therefore, for individual patients in vitro measures of platelet reactivity do not 8	
accurately predict the in vivo effectiveness of DAPT due to the confounding of differences in 9	
endothelial mediator production. To test this hypothesis we added NO and PGI2 to standard 10	






24 healthy, non-smoking male volunteers (aged 18-40 years) were recruited and participated 3	
in the study. Health status was determined though medical history and physical examination, 4	
including blood pressure, pulse rate, blood chemistry and urinalysis. Volunteers with normal 5	
clinical profiles were included in the study. The study was approved by St Thomas’s Hospital 6	
Research Ethics Committee (Ref. 07/Q0702/24) and all volunteers gave written consent 7	
before entering the study. 8	
 9	
Study protocol 10	
Healthy volunteers abstained from aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) 11	
and any other anti-platelet therapy for 14 days before commencing the study. The volunteers 12	
were divided into groups of 8. The first group received aspirin (75 mg; Nu-Seals Cardio 75, 13	
Alliance Pharmaceuticals Ltd, Chippenham, UK), the second prasugrel (10 mg; Effient®, Eli 14	
Lilly, RA Houten, The Netherlands) and the third both aspirin (75 mg) and prasugrel (10 mg) 15	
to represent dual anti-platelet therapy (DAPT), for 7 days. Adherence was assessed by 16	
interview. Blood samples were collected before and after drug treatment. 17	
 18	
Blood collection 19	
Blood for platelet aggregation was collected by venepuncture into tri-sodium citrate (0.32 % 20	
final; Sigma, Poole, Dorset, UK). Platelet-rich plasma (PRP) was obtained by centrifugation 21	
at 175 x g for 15 min at 25˚C. Platelet-poor plasma (PPP) was obtained by centrifugation of 22	
PRP at 15 000 x g for 2 min. All experiments were completed within 2 hr of blood collection. 23	
	 7 
 1	
Incubation with platelet function inhibitors 2	
For in vitro incubation experiments, PRP was treated with either vehicle (0.5% DMSO) or the 3	
P2Y12 receptor blocker prasugrel-active-metabolite (PAM; a kind gift of AstraZeneca) at 1.5 4	
μM, 3 μM or 6 μM, to represent 25%, 50% or 100% of the concentration needed for 5	
complete P2Y12 receptor blockade, respectively, in the absence or presence of aspirin 6	
(acetylsalicylic acid; ASA, 30 μM) for 30 min at 37°C. 7	
 8	
Light transmission aggregometry (LTA) 9	
Baseline aggregation of PRP to arachidonic acid (AA, final concentration, 1 mM; Sigma), 10	
adenosine diphosphate (ADP, 5-20 µM; Labmedics, Salford, Manchester, UK), Horm 11	
collagen (0.4 and 10 µg/mL; Nycomed, Linz, Austria) and U46619 (10 µM; Cayman 12	
Chemical Company, Ann Arbor, MI, USA) was measured in a Bio/Data PAP-8E turbidimetric 13	
aggregometer (1200 rpm, 37°C; Alpha Laboratories, Eastleigh, UK) before and following 14	
treatment. Aggregations to TRAP-6 amide specific for PAR1 (TRAP-6, 25 µM; SFLLRN, 15	
Bachem, Bubendorf, Switzerland) or Horm collagen (4 µg/mL) after pre-incubation (1 min, 16	
37°C) with the NO donor diethlyammonium (Z)-1-(N,N- diethylamino)diazen-1-ium-1,2-17	
diolate (DEA/NONOate, 100 nM; Sigma) and/or prostacyclin (PGI2; 1 nM; R&D systems, 18	
Abingdon, UK) or vehicle (NaOH, 10 mM; Sigma) were also recorded. Using an NO 19	
measuring system (iNO600, Harvard apparatus) we showed 83 nM NO release at 2 mins 20	




Inhibitory concentration curves for PGI2 (1-8 nM) or DEA/NONOate (10 nM – 1 µM) against 3	
aggregation induced by TRAP-6 (25 µM) or collagen (30 µg/mL) in the presence of vehicle 4	
or PAM (6 µM) were constructed with data fitted to a logistic equation using least-squares 5	
method (Prism 6.0e, GraphPad Software, La Jolla, CA, USA). Derived data was used to 6	
generate isobolograms [18, 19]. 7	
 8	
ADP+ATP secretion 9	
PRP was pre-incubated for 1 min with DEA/NONOate, PGI2 or vehicle in an optical lumi-10	
aggregometer (560 CA; Chronolog, Havertown, PA, USA). ADP+ATP secretion was 11	
evaluated by luminescence in the presence of Chrono-Lume reagent (0.2 µM 12	
luciferin/luciferase; Chronolog) after stimulation with TRAP-6 (25 µM) or collagen (4 µg/mL).  13	
 14	
P-selectin expression and GPIIb/IIIa activation 15	
PRP, pre-incubated with PAM or vehicle, as described earlier, was incubated with PGI2, 16	
DEA/NONOate or vehicle and then activated with TRAP-6 (25 µM) with gentle mixing at 37 17	
°C. After 2 min, the reaction was stopped by dilution with a 10-fold excess of cold saline. 18	
Platelets were immediately stained with anti–CD61-allophycocyanin (CD61-APC; 19	
eBioscience, Hatfield, UK), PAC-1-FITC (BD Bioscience, Oxford, UK), and anti–P-selectin-20	
PE (eBioscience) for 15 min at 4°C and then fixed in 2% (vol/vol) formalin (Sigma). PAC-1-21	
FITC and anti–P-selectin-PE immunoreactivity was measured by flow cytometry using a 22	
FACSCalibur instrument (Becton Dickenson, Oxford, UK). Representative histograms are 23	
	 9 
shown in Supplementary Figure 5A-5D. 1	
 2	
VASP phosphorylation 3	
PAM or vehicle-treated PRP was stimulated with collagen (4 µg/mL) or TRAP-6 (25 µM) in 4	
the presence of PGI2, DEA/NONOate or vehicle. After 4 min, the reaction was stopped with 5	
methanol-free formaldehyde (2% final; Fisher Scientific). Platelets were permeabilised (0.2% 6	
Triton X-100; Sigma) and incubated with anti–vasodilator stimulated phosphoprotein 7	
(VASP)-P(Ser239) primary antibody (Enzo Life-sciences, Exeter, UK), Alexa647-conjugated 8	
secondary antibody (Invitrogen, Paisley, UK), and FITC-conjugated anti-CD42b 9	
(eBioscience, Hatfield, UK), for 30 min each, in turn, before the platelet pellet was 10	
resuspended in 0.9% saline. VASP-P(Ser239) immunoreactivity was measured by flow 11	
cytometry, using a FACS-Calibur instrument (Becton Dickenson). Representative histograms 12	
are shown in Supplementary Figure 5E-5F. 13	
 14	
cAMP and cGMP measurements  15	
PAM or vehicle-treated PRP was stimulated with collagen (4 µg/mL) or TRAP-6 (25 µM) in 16	
the presence of PGI2, DEA/NONOate or vehicle. After 4 min, platelets were lysed with 17	
Triton-X-100 (0.625%) and treated with iso-butylmethylxanthine (IBMX; 500 μM) and 18	
potassium fluoride (0.5 M). cAMP and cGMP concentrations were determined by 19	
homogenous time-resolved fluorescence-based competitive immunoassays (Cisbio 20	
Bioassays, Codolet, France). 21	
 22	
Statistics and data analysis 23	
	10 
Data were analysed using Prism 6.0e. Summary data (IC50, EC50) were obtained by fitting of 1	
data to a logistic equation and tested by Student’s t-test (2 groups) or one-way ANOVA (>2 2	
groups). Flow data were analysed using FlowJo v8.7 (Treestar, Ashland, USA) where the 3	
“single platelet” population was gated based on forward scatter and CD61-APC 4	
immunoreactivity (FL-4 mean fluorescence intensity). Statistical significance was determined 5	
by two-way ANOVA with Dunnett’s post-hoc test unless otherwise stated, and data sets 6	
considered different if p<0.05.  7	
 8	




Light transmission aggregation responses following in vivo mono and dual anti-2	
platelet therapy 3	
In individuals taking aspirin, standard LTA responses to AA (1 mM) were strongly inhibited, 4	
as were responses to collagen. Responses to ADP (5 µM) were also significantly reduced, 5	
although to a lesser degree, while those to U46619 (10 µM) were unaffected 6	
(Supplementary Figure 1A). In individuals taking prasugrel, aggregatory responses to AA, 7	
collagen, ADP and U46619 were all significantly reduced (Supplementary Figure 1B). 8	
Aggregations induced by AA, collagen and ADP were abolished in individuals taking DAPT 9	
(Supplementary Figure 1C) while responses to U46619 were strongly reduced.  10	
 11	
Platelet aggregation, ATP secretion, P-selectin expression and GPIIb/IIIa activation in 12	
the presence of PGI2 and DEA/NONOate together with DAPT   13	
In blood from individuals before DAPT, PGI2 (1 nM), DEA/NONOate (100 nM) or 14	
DEA/NONOate+PGI2 had little effect upon platelet aggregation. Following DAPT, collagen (4 15	
µg/ml)-induced aggregation was significantly reduced from 73±2% to 31±2% (p<0.05; Figure 16	
1A & Supplementary Figure 2A), as seen previously with a lower concentration of collagen 17	
(0.4 µg/mL; Supplementary Figure 1A). TRAP-6 (25 µM)-induced aggregation was, however, 18	
unaffected by DAPT unless DEA/NONOate+PGI2 was present, when it was substantially 19	
reduced (67±3% to 19±6%, p<0.05; Figure 1B). In parallel experiments, we used lumi-20	
aggregometry to quantify ADP+ATP release as a measure of dense granule secretion 21	
(Supplementary Figure 2B). These studies indicated that TRAP-6 induced dense granule 22	
secretion was unaffected in individuals receiving DAPT administration but was reduced with 23	
the further addition of DEA/NONOate+PGI2 (6.3±1.9 to 3.7±1.3 nM, p<0.05; Figure 1C). 24	
	12 
Similar effects were found in individuals receiving prasugrel, in whom aggregation in 1	
response to TRAP-6 was significantly reduced (63±3% to 7±3%, p<0.05; Supplementary 2	
Figure 3D) by the addition of DEA/NONOate+PGI2. Treatment with aspirin alone significantly 3	
reduced collagen-induced aggregation in the presence of both DEA/NONOate (58±9% to 4	
36±8%, p<0.05; Supplementary Figure 3A) and PGI2 (66±5% to 35±7, p<0.05; 5	
Supplementary Figure 3A). Following treatment with aspirin, TRAP-6-induced aggregation 6	
was unaffected by DEA/NONOate or PGI2, but was reduced by DEA/NONOate+PGI2 7	
(58±8% to 28±9%, p<0.05; Supplementary Figure 3B). To aid in visualisation of results these 8	
data are also expressed as heatmaps (Supplementary Figures 3E-F). 9	
In individuals receiving DAPT, TRAP-6-induced P-selectin expression (geometric mean 10	
fluorescence index; MFI, 29.0±7.5 units to 2.4±0.6 units, p<0.05; Supplementary Figure 6A) 11	
and PAC-1 binding (12.4±3.4 units to 1.3±0.5 units, p<0.05; Supplementary Figure 6B) were 12	
significantly reduced. This pattern was similar with regard to P-selectin expression (25.0±6.1 13	
units to 8.8±3.4 units, p<0.05) and PAC-1 binding (19.2±3.7 units to 1.6±0.3 units, p<0.05) in 14	
individuals receiving prasugrel only. Treatment with aspirin alone had no effect on either P-15	
selectin or PAC-1 binding. 16	
 17	
Effects of PGI2 and DEA/NONOate on platelet aggregation and ATP release in the 18	
presence of submaximal P2Y12 antagonism is sufficient to produce platelet inhibition  19	
PRP was taken from healthy volunteers and pre-treated in vitro with prasugrel-active 20	
metabolite (PAM; 1.5 µM, 3 µM and 6 µM) to represent 25%, 50% and 100% of the 21	
concentration of PAM required for total P2Y12 receptor inhibition in the absence (Table 1A) 22	
and presence (Table 1B) of aspirin. Aggregation in response to ADP (20 µM) was 23	
increasingly inhibited with increasing levels of PAM: control, 73±5%; aspirin, 51±7%; 24	
	13 
aspirin+PAM-25%, 33±11%; aspirin+PAM-50%, 23±8%; aspirin+PAM-100%, 7±1% 1	
(p<0.05).  2	
Maximum platelet aggregation to collagen in the presence of PAM-100% was reduced by 3	
the addition of DEA/NONOate (74±4% to 23±9%, p<0.05), PGI2 (74±4% to 22±6%, p<0.05) 4	
and DEA/NONOate+PGI2 (50±10% to 4±1%, p<0.05). Similarly, TRAP-induced aggregation 5	
was reduced in the presence of DEA/NONOate (70±2% to 36±6%, p<0.05), PGI2 (67±2% to 6	
35±3%, p<0.05) and DEA/NONOate+PGI2 (63±3% to 4±2%, p<0.05). Indeed, even with 7	
submaximal, PAM-50% and PAM-25% P2Y12 receptor inhibition, significant inhibition of 8	
platelet aggregation was found following addition of DEA/NONOate and PGI2. 9	
  10	
Although aspirin alone inhibited collagen-induced platelet aggregation, TRAP-6-induced 11	
aggregation was only significantly inhibited with the further addition of DEA/NONOate+PGI2 12	
to aspirin+PAM-100% (58±5 to 15±8%, p<0.05), aspirin+PAM-50% (67±6% to 33±15%, 13	
p<0.05), and even aspirin+PAM-25% (70±4% to 36±13%, p<0.05; Table 1B). 14	
 15	
Collagen (4 µg/mL)-induced ATP release was significantly inhibited by DEA/NONOate+PGI2 16	
in the presence of PAM-100% (8.2±2.1 nM to 2.3±0.5 nM), PAM-50% (10.1±2.9 nM to 17	
4.0±1.8 nM, p<0.05) and PAM-25% (11.0±3.0 nM to 4.1±1.7 nM, p<0.05; Table 2A), but not 18	
by DEA/NONOate or PGI2 alone. Similarly, in the presence of aspirin (Table 2B), collagen-19	
induced ATP release was significantly reduced by DEA/NONOate+PGI2 with submaximal 20	
levels of P2Y12 blockade (aspirin+PAM-0%, 8.0±0.5 nM; aspirin+PAM-25%, 1.9±0.3 nM, 21	
p<0.05; aspirin+PAM-50%, 2.1±0.3, p<0.05; aspirin+PAM-100%, 1.8±0.2 nM, p<0.05).  22	
 23	
Synergy between PGI2, DEA/NONOate and P2Y12 blockade 24	
Isobolographic analyses indicated strong synergistic inhibition between DEA/NONOate and 25	
PGI2 against platelet aggregation induced by collagen (30 µg/mL; Figure 2A) or TRAP-6 26	
	14 
amide (25 µM; Figure 2B), with isoboles curving strongly towards the axes.  P2Y12 blockade 1	
caused a further powerful (5-fold and 10-fold, respectively) enhancement in the synergy 2	
between DEA/NONOate and PGI2 for the inhibition of aggregations induced by collagen 3	
(Figure 2B) and TRAP-6 (Figure 2D). 4	
 5	
Involvement of cAMP and cGMP in the synergistic effects of P2Y12 blockade, PGI2 and 6	
DEA/NONOate 7	
We found no significant change in cGMP levels in the platelets in response to 8	
DEA/NONOate and/or PGI2 after incubation with aspirin, PAM or aspirin+PAM after platelet 9	
aggregation stimulated by collagen (Figure 3A) or TRAP-6 (Figure 3B). 10	
In collagen-stimulated platelets, cAMP levels (0.8±0.1 nM) were not altered by 11	
DEA/NONOate, but were significantly increased by PGI2 (2.6±0.3 nM, p<0.05) and even 12	
more so by the combination of DEA/NONOate+PGI2 (4.9±0.6 nM, p<0.05). Neither PAM, 13	
aspirin or PAM+aspirin altered the cAMP response in collagen-stimulated platelets (Figure 14	
3C). In contrast, in TRAP-6-stimulated platelets, DEA/NONOate, PGI2 and the combination 15	
did not elevate cAMP levels in vehicle or aspirin groups, but did in the presence of PAM 16	
(1.0±0.1 nM to 2.3±0.2 nM, p<0.05) or PAM+aspirin (1.4±0.5 nM to 2.2±0.4 nM, p<0.05), 17	
PGI2 increased cAMP levels and this response was further enhanced by addition of 18	
DEA/NONOate (PAM: 3.4±0.6 nM, PAM+aspirin: 3.5±0.6 nM, p<0.05; Figure 3D). 19	
Phospho (Ser239)-VASP, a downstream marker of PKG activation, remained unchanged in 20	
most conditions studied but was increased following TRAP-6 stimulation in the presence of 21	
PAM in all cases and most so in the presence of PGI2 (28±5 to 47±15 units, p<0.05) or 22	




Here we show in healthy individuals receiving standard DAPT leading to consensus levels of 2	
platelet inhibition that ex vivo responses to the strong primary platelet activators collagen 3	
and TRAP-6 are powerfully influenced by the presence of NO and PGI2. The strong 4	
synergies between P2Y12 inhibitors and the cAMP and cGMP signaling systems mean that 5	
the in vivo platelet reactivity in patients receiving DAPT will be a function of the level of 6	
P2Y12 receptor blockade and the levels of endothelium-derived NO and PGI2. This provides 7	
an explanation for different thrombotic outcomes in the presence of similar levels of platelet 8	
blockade; i.e. individual patients with different levels of endothelial function, or indeed 9	
disease-driven endothelial dysfunction, would have different levels of in vivo platelet 10	
inhibition for the same level of DAPT activity, as determined by ex vivo testing.  11	
DAPT, aspirin plus a P2Y12 receptor blocker, is the preventative therapy provided to patients 12	
at particular risk of coronary thrombosis, notably for the first 12 months following coronary 13	
stent implantation or an acute coronary syndrome [20, 21]. Despite this therapeutic 14	
approach coronary thrombosis still occurs, and there have been great efforts made to find ex 15	
vivo tests that could predict for clinical outcomes [22, 23]. Deductive reasoning leads to the 16	
conclusion that less effective platelet blockade would leave individuals at increased risk of 17	
thrombosis and so multiple efforts have been made to link levels of platelet reactivity in ex 18	
vivo tests to clinical outcomes. Despite the attractive logic of this approach, tailoring anti-19	
platelet therapy to ex vivo platelet responses has failed to provide any improvement in 20	
clinical outcomes as noted in large scale studies such as ADRIE [24] and several large-scale 21	
prospective, randomised clinical trials, such as GRAVITAS [7], ARCTIC [8], TRIGGER-PCI 22	
[9] and TRILOGY [10].  23	
In patients receiving clopidogrel, there are well-characterised metabolic differences that can 24	
produce suboptimal levels of its active metabolite and consequently result in suboptimal 25	
levels of P2Y12 receptor blockade [25]. There are also some reports of variability in the 26	
	16 
effects of prasgurel and ticagrelor, although to a much lesser extent than for clopidogrel [26]. 1	
Biochemical resistance to the effects of aspirin are also particularly rare [27]. Allowing for 2	
differences dependent upon adherence to therapy, individuals on DAPT may in fact present 3	
rather a more homogenous level of platelet inhibition than can be associated to different 4	
clinical outcomes. Having recently reported that blockade of P2Y12 receptors greatly 5	
increases the inhibitory effects of NO, and knowing that not only was there a similar 6	
interaction with the inhibitory effects of PGI2 but that NO and PGI2 powerfully synergise to 7	
inhibit platelets, we reasoned that differences in the levels of NO and PGI2 in the presence of 8	
the same levels of P2Y12 receptor blockade would produce different levels of platelet 9	
inhibition. By testing this hypothesis in individuals receiving standard DAPT we show here 10	
that strong and synergistic interactions between P2Y12 receptor blockade and endothelium-11	
derived mediators produce profound inhibitory effects upon platelets. We firstly established 12	
that the drug regime given in our studies elicited satisfactory reduction in baseline reactivity, 13	
therefore establishing effectiveness of P2Y12 and/or COX inhibition in accordance with 14	
suggested analytical cutoffs [28]. These reductions were against high pre-treatment levels of 15	
platelet reactivity (>70% response to 5 µM ADP) [29]. In these studies, and others presented 16	
here, we took care to include the standard measures of platelet function as determined in 17	
consensus statements [28, 30]. Then to make data readily accessible we have presented 18	
results in the form of heat maps that move from red to green, indicating movement from full 19	
platelet activation to no platelet activation. 20	
It is well known that NO and PGI2 synergise to inhibit platelets [12] and it has been 21	
demonstrated by ourselves and others that P2Y12 antagonists potentiate the inhibitory 22	
actions of both PGI2, dependent upon cAMP [17], and NO, dependent upon cGMP 23	
generation [18]. Here, we have shown that this synergy, in the presence of NO and PGI2 is 24	
mostly cAMP dependent, therefore phosphodiesterase 3 (PDE3) inhibitors, such as 25	
cilostazol, may have an enhanced effect compared to PDE5 inhibitors, such as sildenafil. 26	
Though not widely commented upon, the body contains many more endothelial cells than 27	
	17 
platelets, in the order of 50 times more, and the two populations constantly interact. In the 1	
circulation DAPT exerts its effects upon platelets in the presence of endothelium-derived 2	
mediators while these are absent in ex vivo testing.  In the studies presented here we found 3	
that the interactions of NO, PGI2 and P2Y12 receptor blockade in inhibiting platelets were 4	
markedly synergistic as noted by isobolographic analysis and measures of aggregation, ATP 5	
release, activation of GP IIb/IIIa receptors and P-selectin expression. In volunteers taking 6	
DAPT we noted inhibition of responses to ADP and AA that were in keeping with consensus 7	
statements of effective DAPT; i.e. in our study the drugs were working to an effective level of 8	
clinical efficacy. Despite this level of effective inhibition, high concentrations of the strong 9	
primary platelet activators, TRAP-6 or collagen, still caused notable platelet activation.  10	
Addition of low concentrations of NO and PGI2, to model the environment within the blood 11	
vessel, had little effect on their own but led to almost complete inhibition in platelets from 12	
individuals treated with DAPT. Similarly, while NO, PGI2 or DAPT alone had relatively little 13	
effect upon platelet granule release, determined as ATP release, when combined they 14	
caused more than 50% inhibition. These results indicate that even in the presence of 15	
effective DAPT, i.e. within consensus guidelines, the presence of NO and PGI2 lead to very 16	
much higher levels of platelet inhibition.        17	
Next using an in vitro approach we modeled events in the presence of suboptimal levels of 18	
P2Y12 receptor blockade by using concentrations of PAM that were 50% and 25% of the 19	
effective concentration.  Under these conditions we noted that relative to the consensus 20	
levels of DAPT we did not achieve significant reduction in platelet aggregation. Notably, 21	
however, in the presence of NO and PGI2 effective levels of inhibition were achieved, even 22	
when platelets were exposed to only 25% of the effective concentration of PAM. As we 23	
express in heat maps, there is a clear interaction between DAPT and the endothelial 24	
mediators that move platelets from reactive (‘red’) to unreactive (‘green’). Interestingly, these 25	
comparisons indicate that 25% of the effective concentration of PAM plus NO and PGI2 26	
produces a stronger inhibition in LTA, the ‘gold standard test’, than 100% of the effective 27	
	18 
concentration of PAM in the absence of NO and PGI2 (i.e. the normal conditions for testing 1	
ex vivo platelet responsiveness). This suggests that in individuals in whom suboptimal P2Y12 2	
inhibition is achieved, such as poor clopidogrel metabolisers, anti-platelet efficacy may be 3	
particularly sensitive to any changes in endothelial function. Our in vitro data also 4	
demonstrate that the triple synergy between P2Y12 blockade, NO and PGI2 can be explained 5	
by changes in cAMP signaling, which is consistent with known interactions between NO and 6	
PGI2 [31] and PGI2 and P2Y12 [17].  7	
We show that following standard DAPT the level of platelet reactivity is a function of the level 8	
of P2Y12 receptor blockade and the levels of NO and PGI2.  While we added NO and PGI2 9	
exogenously they are surrogates for the effects of endogenous NO and PGI2 and other 10	
elevators of platelet cyclic nucleotides such as adenosine. We propose that, since in vivo 11	
platelet function is a product of both internal platelet responsive signaling reactivity and the 12	
external influence of the endothelium, an assessment of endothelial mediator production 13	
could be combined with results from ex vivo platelet testing to better predict thrombotic 14	
outcomes in individual patients. Furthermore, with the emergence of this complex and very 15	
powerful synergy between PGI2, NO and P2Y12 inhibitors (Figure 4), we should perhaps 16	
consider optimising the availability and activity of endothelium-derived mediators (such as 17	
PDE inhibitors), or providing mimetic drugs, rather than adding in further anti-platelet 18	
therapies. These findings could, eventually, be applied in a personalised medicine 19	
framework where the endothelial mediator production of individuals is assessed and 20	
appropriate add-on therapy applied. In a more generalised approach these additional 21	
therapies could also be supplied to patient groups with known endothelial dysfunction, such 22	
as diabetics. This approach could provide increased anti-platelet efficacy while avoiding the 23	
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LEGENDS TO TABLES & FIGURES 1	
 2	
Table 1. In vitro effects of aspirin and PAM on platelet aggregation. PRP from healthy 3	
volunteers (n = 4) was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 50% 4	
and 100% maximum concentration for total P2Y12 receptor inhibition, respectively. Tables 5	
show % final aggregation in response to ADP (20 µM), collagen (4 µg/mL) and TRAP-6 (25 6	
µM) in the presence of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or NO + PGI2 in 7	
the (A) absence and (B) presence of aspirin (30 µM). Significance is shown as * p<0.05 vs 8	
vehicle, † p<0.05 vs PGI2. 9	
 10	
Table 2. In vitro effects of aspirin and PAM on ATP release. PRP from healthy volunteers 11	
(n = 4) was treated with PAM (1.5 µM, 3 µM and 6 µM) to represent 25%, 50% and 100% 12	
maximum concentration for total P2Y12 receptor inhibition, respectively. Tables show ATP 13	
release (nM) in response to collagen (4 µg/mL) and TRAP-6 (25 µM) in the presence of 14	
vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or NO + PGI2 in the (A) absence and (B) 15	
presence of aspirin (30 µM). Significance is shown as * p<0.05 vs vehicle, † p<0.05 vs PGI2. 16	
 17	
 18	
Figure 1. Interactions of NO and PGI2 with DAPT: platelet aggregation & ATP release. 19	
Bar graphs and heatmaps of platelet aggregation in response to (A) collagen (4 µg/ml), and 20	
(B) TRAP-6 amide (25 µM), and (C) ATP release in response to TRAP-6 amide (25 µM). 21	
Aggregometry was conducted before and after 7 days DAPT (aspirin, 75 mg, plus prasugrel, 22	
10 mg). Aggregometry conducted in the presence of vehicle (NaOH, 10 mM), NO (100 nM), 23	
PGI2 (1 nM), or NO + PGI2. Data are presented as final aggregation (%, mean±SEM) or ATP 24	
	24 
release (nM, mean±SEM). Heatmaps indicate maximum aggregation or ATP release with 1	
red and minimum aggregation or ATP release with green. N = 8 for all. Significance is shown 2	
as * p<0.05 vs non-treated, † p<0.05 vs NaOH DAPT-treated ‡ p<0.05 vs PGI2 DAPT-3	
treated. 4	
 5	
Figure 2. Synergism between NO, PGI2 and PAM. IC50 isobolograms were generated by 6	
analysing combinations of NO and PGI2 required to produce a 50% inhibition of platelet 7	
aggregation stimulated by: collagen (30 µg/mL) in the (A) absence and (B) presence of PAM 8	
(6 µM); and, by TRAP-6 (25 µM) in the (C) absence and (D) presence of PAM. The linear 9	
relationship is predicted by the arithmetic sum of the effect of either NO or PGI2 alone, as 10	
described in the methods, and the experimental line curving towards the axes indicates a 11	
strong, synergistic relationship. N = 4 for each point. 12	
 13	
Figure 3. In vitro effects of aspirin and PAM on cyclic nucleotide levels. PRP from 14	
healthy volunteers (n = 4) was treated with aspirin (30 µM), PAM (6 µM) or both followed by 15	
addition of vehicle (NaOH, 10 mM), NO (100 nM), PGI2 (1 nM) or NO + PGI2. cGMP levels 16	
were then measured following stimulation by (A) collagen (4 µg/mL) and (B) TRAP-6 (25 17	
µM); as were cAMP levels following (C) collagen and (D) TRAP-6. Phospho (Ser239)-VASP 18	
levels in (E) collagen and (F) TRAP-6-stimulated PRP were determined by flow cytometry as 19	
a composite of cGMP and cAMP responses. Significance is shown as * p<0.05 vs non-20	
treated and † p<0.05 vs PGI2 with corresponding PAM or aspirin+PAM. 21	
 22	
Figure 4. Summary of the interaction between the endothelium and P2Y12 antagonism. 23	
In the healthy intact circulation platelets are kept in a non-activated state in part by the action 24	
	25 
of endothelium-derived mediators, NO and PGI2. At areas of endothelial damage platelets 1	
become activated leading to platelet adherence and activation. This effect is partly driven by 2	
stimulation of P2Y12 receptors following from platelet release of ADP. This stimulation of 3	
P2Y12 receptors inhibits the effects of cAMP and cGMP within platelets, making platelets 4	
more excitable, and amplifying platelet activation.  When P2Y12 receptors are blocked, cAMP 5	
and cGMP pathways are not inhibited by ADP and the inhibitory effects of NO and PGI2 are 6	
sustained.  The inhibitory effectiveness of P2Y12 receptor blockade and DAPT in vivo is 7	
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SUPPORTING LEGENDS TO FIGURES 1	
 2	
Supplementary Figure 1. Standard platelet aggregation tests. Standard light 3	
transmission aggregometry responses to AA (1 mM), ADP (5 µM), collagen (0.4 4	
µg/mL) and U46619 (10 µM) in healthy volunteers before and following treatment 5	
with (A) aspirin (75 mg), (B) prasugrel (10 mg), or (C) DAPT (aspirin, 75 mg, plus 6	
prasugrel, 10 mg) for 7 days. N=8 for all.  Significance is shown as * p<0.05 vs non-7	
treated. 8	
 9	
Supplementary Figure 2. The effect of DAPT on platelet aggregation and ATP 10	
release. Representative light transmission aggregometry traces of PRP before and 11	
after DAPT (aspirin, 75 mg, plus prasugrel, 10 mg) treatment in the presence of 12	
vehicle (NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM), or 13	
DEA/NONOate+PGI2 following stimulation with (A) collagen (4 μg/mL) or (B) TRAP-6 14	
amide (25 μM). (C) Representative lumi-aggregometry traces in the same conditions 15	
after TRAP-6 amide (25 μM) stimulation, where ATP release is measured as an 16	
increase in voltage.  17	
 18	
Supplementary Figure 3. The effect of aspirin and prasugrel on platelet 19	
aggregation. Healthy volunteers (n = 8) were treated with aspirin (75 mg) or 20	
prasugrel (10 mg) for 7 days. Aggregometry was conducted in the presence of 21	
vehicle (NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate  + 22	
PGI2 before and after aspirin, using as agonists (A) collagen (4 µg/mL) or (B) TRAP-6 23	
amide (25 µM), and before and after prasugrel, also using (C) collagen (4 µg/mL) or 24	
(D) TRAP-6 amide (25 µM). Data are presented as final aggregation (%, 1	
mean±SEM). Summary heatmaps after stimulation with (E) collagen (4 µg/mL) or (F) 2	
TRAP-6 amide (25 µM) indicate maximum aggregation with red and minimum 3	
aggregation with green, before treatment and after aspirin (75 mg), prasugrel (10 4	
mg), or DAPT for 7 days. N = 8 for all. Significance is shown as * p<0.05 vs non-5	
treated, † p<0.05 vs NaOH drug-treated ‡ p<0.05 vs PGI2 drug-treated. 6	
 7	
Supplementary Figure 4. The effect of aspirin and prasugrel on platelet ATP 8	
release. Healthy volunteers (n = 8) were treated with aspirin (75 mg) or prasugrel (10 9	
mg) for 7 days. Lumi-aggregometry was conducted in the presence of vehicle 10	
(NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM), or DEA/NONOate + PGI2 11	
before and after (A) aspirin or (B) prasugrel, using collagen (4 µg/mL) as an agonist. 12	
Data are presented as maximum ATP release (%, mean±SEM). (C) A summary 13	
heatmap after stimulation with collagen (4 µg/mL) indicates maximum ATP release 14	
with red and minimum ATP release with green before treatment and after aspirin (75 15	
mg), prasugrel (10 mg) or DAPT for 7 days. N = 8 for all. Significance is shown as * 16	
p<0.05 vs non-treated, † p<0.05 vs NaOH drug-treated ‡ p<0.05 vs PGI2 drug-17	
treated. 18	
 19	
Supplementary Figure 5. Representative control data for flow cytometry 20	
experiments. GPIIb/IIIa activation by PAC-1 binding in the (A) absence and (B) 21	
presence of DAPT, P-selectin expression in the (C) absence and (D) presence of 22	
DAPT and VASP phosphorylation (Ser239) in the (E) absence and (F) presence of 23	
DAPT was measured by flow cytometry in PRP stimulated with TRAP-6 (25 μM) in 24	
the presence of vehicle (NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM), or 25	
DEA/NONOate + PGI2. Histograms are representative of n = 3.  1	
 2	
Supplementary Figure 6. The effect of aspirin, prasugrel and DAPT on P-3	
selectin and glycoprotein IIb/IIIa. Healthy volunteers (n = 8) were treated with 4	
aspirin (75 mg), prasugrel (10 mg), or DAPT for 7 days. Heatmaps in response to 5	
TRAP-6 amide (25 μM)-stimulated PRP before and after DAPT treatment in the 6	
presence of vehicle (NaOH, 10 mM), DEA/NONOate (100 nM), PGI2 (1 nM) or 7	
DEA/NONOate+PGI2 were generated for (A) CD62P (P-selectin) and (B) PAC-1 8	
(GPIIb/IIIa binding). Red represents maximum expression and green shows minimum 9	
expression with each cell representing data from 3 groups of 8 subjects. 	10	






